MoonLake Immunotherapeutics | 8-K: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.84, beating the estimate of USD -0.926.

EBIT: As of FY2026 Q2, the actual value is USD -59.08 M.

Financial Position

MoonLake Immunotherapeutics reported cash, cash equivalents, and short-term marketable debt securities totaling $537.0 million as of June 30, 2026, an increase from $357,921 thousand as of March 31, 2026, which included cash and cash equivalents of $298,490 thousand and short-term marketable debt securities of $59,431 thousand.

Operating Expenses

Research and development expenses for the three months ended June 30, 2026, were - $50,221 thousand, a decrease from - $54,515 thousand for the three months ended March 31, 2026. General and administrative expenses were - $11,439 thousand for the three months ended June 30, 2026, down from - $15,509 thousand for the three months ended March 31, 2026. This decrease of $4.1 million was primarily due to a $4.8 million accelerated expense recognition in the prior quarter related to a voluntary cancellation of unvested stock option awards. Total operating expenses for the three months ended June 30, 2026, were - $61,660 thousand, compared to - $70,024 thousand for the three months ended March 31, 2026.

Operating Loss and Net Loss

The company reported an operating loss of - $61,660 thousand for the three months ended June 30, 2026, versus - $70,024 thousand for the three months ended March 31, 2026. The net loss was - $61,805 thousand for the three months ended June 30, 2026, compared to - $69,707 thousand for the three months ended March 31, 2026. Basic and diluted net loss per share was - $0.84 for the three months ended June 30, 2026, an improvement from - $0.98 for the three months ended March 31, 2026.

Other Financial Items

Interest expense was - $2,632 thousand for the three months ended June 30, 2026, and - $2,269 thousand for the three months ended March 31, 2026. Other income, net, was $2,577 thousand and $3,208 thousand for the respective periods. Income tax expense was - $90 thousand for the three months ended June 30, 2026, and - $622 thousand for the three months ended March 31, 2026. Comprehensive loss was - $61,497 thousand for the three months ended June 30, 2026, compared to - $69,989 thousand for the three months ended March 31, 2026.

Balance Sheet Highlights

Total assets increased to $573,947 thousand as of June 30, 2026, from $400,374 thousand as of March 31, 2026. Total liabilities were $145,752 thousand as of June 30, 2026, a slight decrease from $146,350 thousand as of March 31, 2026. Total shareholders’ equity rose to $428,195 thousand as of June 30, 2026, from $254,024 thousand as of March 31, 2026. The accumulated deficit was - $594,423 thousand as of June 30, 2026, compared to - $532,618 thousand as of March 31, 2026.

Operational Metrics (IZAR-1 Phase 3 Trial Results)

MoonLake Immunotherapeutics announced positive topline results from the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis, with the 60 mg sonelokimab with induction arm meeting all clinical endpoints at Week 16. The primary endpoint of ACR50 was met with a 42.1% response rate. Key secondary endpoints showed significant responses: ACR20 at 66.5%, MDA at 41.2%, and PASI90 at 61% in patients with concomitant skin involvement. Clinically meaningful improvements were also observed in patient-reported outcomes, with a mean change from baseline in HAQ-DI of -0.427 and an improvement in SF-36 Physical Component Summary (PCS) score of 6.54. The blinded safety analysis indicated a profile consistent with previous studies, with no new safety signals identified.

Outlook / Guidance

MoonLake Immunotherapeutics anticipates a cash runway extending to mid-2028, supported by up to $400 million in non-dilutive funds from its debt facility. Key upcoming milestones include the expected submission of a Biologics License Application (BLA) for HS by the end of September 2026, and the expected allocation of a PDUFA date and decision on Priority Review by the end of November 2026. The company also expects to commence enrollment in the Palmoplantar Pustulosis (PPP) Phase 3 trial in H2 2026, complete enrollment in the PsA – IZAR-2 trial in Q3 2026, and report results from the P-OLARIS trial by the end of 2026 or early 2027.